1. Home
  2. KW vs VIR Comparison

KW vs VIR Comparison

Compare KW & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kennedy-Wilson Holdings Inc.

KW

Kennedy-Wilson Holdings Inc.

HOLD

Current Price

$11.00

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$8.54

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KW
VIR
Founded
1977
2016
Country
United States
United States
Employees
N/A
367
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2007
2019

Fundamental Metrics

Financial Performance
Metric
KW
VIR
Price
$11.00
$8.54
Analyst Decision
Sell
Strong Buy
Analyst Count
1
7
Target Price
$11.00
$19.43
AVG Volume (30 Days)
740.2K
1.4M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
4.41%
N/A
EPS Growth
50.00
17.49
EPS
0.10
N/A
Revenue
$62,633,000.00
$68,556,000.00
Revenue This Year
$81.79
$270.22
Revenue Next Year
N/A
N/A
P/E Ratio
$110.30
N/A
Revenue Growth
23.94
N/A
52 Week Low
$5.98
$4.16
52 Week High
$11.09
$11.66

Technical Indicators

Market Signals
Indicator
KW
VIR
Relative Strength Index (RSI) 59.87 35.05
Support Level $10.82 $8.47
Resistance Level $11.09 $10.29
Average True Range (ATR) 0.03 0.41
MACD 0.00 -0.18
Stochastic Oscillator 60.47 0.26

Price Performance

Historical Comparison
KW
VIR

About KW Kennedy-Wilson Holdings Inc.

Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; the Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: